Kymera therapeutics, inc.KYMR.US Overview
KYMR Overall Performance
KYMR AI Analysis & Strategy
KYMR Recent Performance
-2.69%
Kymera therapeutics, inc.
0.81%
Avg of Sector
-1.14%
S&P500
KYMR PowerScanner
KYMR Key Information
KYMR Valuation Metrics
KYMR Earnings Table
KYMR Profile
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.